Prognostic role and predictors of lymph node involvement in pancreatic neuroendocrine tumors

Abstract

PurposeTo define the prognostic role of lymph node involvement (LNI) in patients with pancreatic neuroendocrine tumors (PNETs) and identify predictors of LNI using a comprehensive multifactor analysis focusing on preoperative radiological features. MethodsThis study included 236 patients with preoperative computed tomography who underwent radical surgical resection of PNETs at our hospital between 2009 and 2019. Univariate and multivariable logistic regression analyses were performed to investigate the risk factors associated with LNI and tumor recurrence. The disease-free survival (DFS) rates with and without LNI were compared. ResultsForty-four of the 236 patients (18.6%) had LNI. Biliopancreatic duct dilatation (odds ratio [OR], 2.295; 95% confidence interval [CI], 1.046–5.035; p = 0.038), tumor margin (OR, 2.189; 95% CI, 1.034–4.632; p = 0.041), and WHO grade (G2: OR, 2.923; 95% CI, 1.005–8.507; p = 0.049; G3: OR, 12.067; 95% CI, 3.057–47.629; p < 0.001) were independent risk factors of LNI in PNETs. Multivariable analysis showed that LNI (OR, 2.728; 95% CI, 1.070–6.954; p = 0.036), G3 (OR, 4.894; 95% CI, 1.047–22.866; p = 0.044), and biliopancreatic duct dilatation (OR, 2.895; 95% CI, 1.124–7.458; p = 0.028) were associated with PNET recurrence in patients after surgery. Patients with LNI had a significantly worse DFS than those without LNI (3‐year DFS: 85.9 vs. 96.7%; p < 0.001; 5‐year DFS: 65.1 vs. 93.9%; p < 0.001). ConclusionLNI was associated with decreased DFS. Biliopancreatic duct dilatation, irregular tumor margins, and grades G2 and G3 were independent risk factors for LNI.